Drug of last resort

A drug of last resort (DoLR) is a pharmaceutical drug that is tried after all other drug options have failed to produce an adequate response in the patient. Drug resistance, such as antimicrobial resistance or antineoplastic resistance, may make the first-line drug ineffective, especially with multidrug-resistant pathogens or tumors. Such an alternative may be outside of extant regulatory requirements or medical best practices, in which case it may be viewed as salvage therapy.

General

The use of a drug of last resort may be based on agreement among members of a patient's care network, including physicians and healthcare professionals across multiple specialties, or on a patient's desire to pursue a particular course of treatment and a practitioner's willingness to administer that course. Certain situations such as severe bacterial related sepsis or septic shock can more commonly lead to situations in which a drug of last resort is used.

Therapies considered to be drugs of last resort may at times be used earlier in the event that an agent would likely show the most immediate dose-response related efficacy in time-critical situations such as high mortality circumstances. Many of the drugs considered to be of last resort fall into one or more of the categories of antibiotics, antivirals, and chemotherapy agents. These agents often exhibit what are considered to be among the most efficient dose-response related effects, or are drugs for which few or no resistant strains are known.

With regard to antibiotics, antivirals, and other agents indicated for treatment of infectious pathological disease, drugs of last resort are commonly withheld from administration until after the trial and failure of more commonly used treatment options to prevent the development of drug resistance. One of the most commonly known examples of both antimicrobial resistance and the relationship to the classification of a drug of last resort is the emergence of Staphylococcus aureus (MRSA) (sometimes also referred to as multiple-drug resistant S. aureus due to resistance to non-penicillin antibiotics that some strains of S. aureus have shown to exhibit). In cases presenting with suspected S. aureus, it is suggested by many public health institutions (including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) in the United States) to treat first with empirical therapies for S. aureus, with an emphasis on evaluating the response to initial treatment and laboratory diagnostic techniques to isolate cases of drug resistance.

Due to the possibility of potential severe or fatal consequences of resistant strains, initial treatment often includes concomitant administration of multiple antimicrobial agents that are not known to show cross-resistance, so as to reduce the possibility of a resistant strain remaining inadequately treated by a single agent during the evaluation of drug response. Once a specific resistance profile has been isolated via clinical laboratory findings, treatment is often modified as indicated.

Vancomycin has long been considered a drug of last resort, due to its efficiency in treating multiple drug-resistant infectious agents and the requirement for intravenous administration. Recently, resistance to even vancomycin has been shown in some strains of S. aureus (sometimes referred to as vancomycin resistant S. aureus (VRSA) or vancomycin intermediate-resistance S. aureus (VISA)) often coinciding with methicillin/penicillin resistance, prompting the inclusion of newer antibiotics (such as linezolid) that have shown efficacy in highly drug-resistant strains. There are also strains of enterococci that have developed resistance to vancomycin referred to as Vancomycin resistant enterococcus (VRE).

Agents classified as fourth-line (or greater) treatments or experimental therapies could be considered by default to be drugs of last resort due to their low placement in the treatment hierarchy. Such placement may result from a multitude of considerations, including greater efficacy of other agents, socioeconomic considerations, availability issues, unpleasant side effects or similar issues relating to patient tolerance. Some experimental therapies might also be called drugs of last resort when administered following the failure of all known and currently accepted treatments.

Despite the fact that most of the notable drugs of last resort are antibiotics or antivirals, other drugs are sometimes considered drugs of last resort, such as cisapride.^[1]

Examples

• Amikacin
• Amphotericin B
• Carbapenems—used as drug of last resort for a variety of different bacterial infections.
• Clomethiazole—a highly toxic sedative/hypnotic agent used in the treatment of alcohol withdrawal and detoxification when benzodiazepines are not effective or appropriate.
• Chloramphenicol—formerly first-line therapy for Rocky Mountain Spotted Fever (until doxycycline became available).^[2] Also first-line therapy (used topically) for bacterial conjunctivitis, and systemically for meningitis when allergies to penicillin or cephalosporin exist. Unacceptably high risk of irreversible, fatal aplastic anemia and gray baby syndrome causes systemically administered chloramphenicol to be a drug of last resort.^[3]
• Cisapride
• Clozapine^[4]—used in treatment-resistant schizophrenia not responsive to at least two different antipsychotics; the main reason for such restriction is agranulocytosis and other severe side effects including seizures and myocarditis.
• Colistin
• Imipenem/cilastatin
• Linezolid
• Levosimendan—used in acutely decompensated severe chronic heart failure in situations where conventional therapy is not sufficient.
• Milrinone
• Oral minoxidil for hypertension,^[5][6] however topical minoxidil is the first line drug for hair loss.
• Polymyxin antibiotics.
• Thalidomide—withdrawn in 1961 owing to widespread incidence of severe birth defects (phocomelia and absence or truncation of limbs) after prenatal use by pregnant women, US Food and Drug Administration approved thalidomide for erythema nodosum leprosum (ENL) in 1998, and 2008 for new cases of multiple myeloma (administered with dexamethasone). A large "off-label" business in thalidomide began for "orphan" cancers and other rare conditions even while it was only FDA-approved for erythema nodosum leprosum.
• Tolcapone—used in patients with Parkinson's disease who are not appropriate candidates for other adjunctive therapies. Use is restricted due to high chances of hepatotoxicity.
• Vancomycin—while this is a very well-tolerated antibacterial, its usefulness only as an injectable and potency in treatment of infection with multiple drug-resistant organisms has caused a growing trend to reserve it for these uses to avoid the spread of vancomycin resistance (in hopes that it will remain useful in intensive care units and other settings where methicillin-resistant staphylococcus aureus (MRSA) and other drug-resistant organisms are a problem).
• Vigabatrin—used in treatment-resistant epilepsy due to the risk of irreversible vision loss.

References